Also called
ICD-10
Specialty
Onset
Reviewed
-
OverviewOverview
-
Etiology & Risk FactorsEtiology & Risk Factors
-
PathophysiologyPathophysiology
-
Clinical PresentationClinical Presentation
-
History TakingHistory Taking
-
Physical ExaminationPhysical Examination
-
InvestigationsInvestigations
-
DiagnosisDiagnosis
-
ManagementManagement
-
ComplicationsComplications
-
PrognosisPrognosis
-
Key Points / Clinical PearlsKey Points / Clinical Pearls
Overview
Cystic fibrosis mainly affects the:
- Lungs
- Pancreas
- Gastrointestinal tract
- Sinuses
- Reproductive system
- Sweat glands
Abnormally thick mucus causes airway obstruction, recurrent lung infections, and progressive lung damage.
Etiology & Risk Factors
-Cause:
Cystic fibrosis is caused by mutations in the CFTR gene.
-Inheritance
- Autosomal recessive
- Both parents usually carry one abnormal CFTR gene
-Common Mutation
F508del is the most common CFTR mutation.
-Risk Factors
- Family history of cystic fibrosis
- Sibling with cystic fibrosis
- Parents who are CFTR mutation carriers
Pathophysiology
CFTR gene mutation
⬇
Abnormal chloride and bicarbonate transport
⬇
Reduced water movement into secretions
⬇
Thick, dehydrated mucus
⬇
Impaired mucus clearance
⬇
Airway obstruction + Bacterial infection
⬇
Chronic inflammation
⬇
Bronchiectasis and progressive lung damage
Other Organs
Thick pancreatic secretions
→ Duct obstruction
→ Pancreatic insufficiency
→ Malabsorption
Abnormal sweat gland function
→ Increased salt loss in sweat
Clinical Presentation
-Respiratory Features
Chronic cough
Persistent sputum production
Recurrent chest infections
Wheezing
Dyspnea
Bronchiectasis
Hemoptysis
-Gastrointestinal Features
Poor weight gain
Malabsorption
Steatorrhea
Abdominal symptoms
Pancreatic insufficiency
-Other Features
Salty-tasting skin
Chronic sinusitis
Nasal polyps
Digital clubbing
Male infertility
-In Newborns
Meconium ileus
Failure to thrive
History Taking
- Chronic cough?
- Daily sputum?
- Recurrent chest infections?
- Wheezing or dyspnea?
- Previous bronchiectasis?
- Poor weight gain?
- Greasy or bulky stools?
- Abdominal symptoms?
- Chronic sinus problems?
- Nasal polyps?
- Salty-tasting skin?
Physical Examination
-General Examination
Look for:
- Low body weight
- Poor growth
- Digital clubbing
- Cyanosis in advanced disease
- Respiratory distress
-Chest Examination
- Coarse crackles
- Wheezing
- Reduced air entry in advanced disease
-Other Findings
- Nasal polyps
- Signs of malnutrition
- Abdominal distension
- Signs of chronic liver disease in advanced cases
Investigations
-Sweat Chloride Test — Key Test
Measures the chloride concentration in sweat.
An elevated sweat chloride level supports the diagnosis.
-CFTR Genetic Testing
Used to:
Identify CFTR mutations
Confirm the diagnosis
Determine eligibility for CFTR modulator therapy
-Newborn Screening
May detect cystic fibrosis before symptoms develop.
-Respiratory Tests
Sputum culture
Pulmonary function tests
Chest X-ray
CT chest
-Other Tests
Pancreatic function testing
Nutritional assessment
Blood glucose monitoring
Liver function tests
Diagnosis
-Diagnosis is based on:
1. Clinical Features or Positive Newborn Screening
Together with:
2. Evidence of CFTR Dysfunction
Demonstrated by:
- Abnormal sweat chloride testing
- CF-causing CFTR mutations
- Specialized CFTR functional testing when needed
Important Note
The sweat chloride test is the main diagnostic test for cystic fibrosis.
Related Topics
Management
Cystic Fibrosis · Treatment
| Treatment Category | Drug / Intervention | Notes |
|---|---|---|
| CFTR Modulator — Triple Combination | Elexacaftor / Tezacaftor / Ivacaftor (ETI, Kaftrio/Trikafta) | For F508del (at least one copy, ~90% of patients). Most effective modulator available — dramatic improvement in FEV1, quality of life, and exacerbation rate. Now first-line where eligible. |
| CFTR Modulator — Potentiator | Ivacaftor (Kalydeco) | For gating mutations (G551D and others). Opens dysfunctional CFTR channels. Not effective for F508del alone. |
| CFTR Modulator — Dual | Lumacaftor / Ivacaftor (Orkambi) or Tezacaftor / Ivacaftor (Symkevi) | For homozygous F508del if ETI not yet available or tolerated. Less effective than ETI. |
| Mucociliary Clearance | Dornase alfa (DNase) inhaled daily — Hypertonic saline 7% inhaled | Dornase alfa cleaves extracellular DNA, reducing sputum viscosity. Hypertonic saline hydrates airway surface. Use bronchodilator first, then mucolytic, then physiotherapy. |
| Chronic Antibiotic Suppression | Inhaled tobramycin alternating months — Inhaled aztreonam — Oral azithromycin (3x/week) | Targets chronic Pseudomonas colonisation. Azithromycin has anti-inflammatory properties independent of antimicrobial effect. Alternate-month inhaled regimens reduce resistance. |
| Acute Pulmonary Exacerbation | IV antipseudomonal antibiotics (e.g. piperacillin-tazobactam + tobramycin or meropenem) | Based on most recent sputum sensitivities. IV for moderate-severe exacerbations; oral for mild. Minimum 14-day course. Intensify airway clearance throughout. |
| Pancreatic Enzyme Replacement | Creon (pancrelipase) with every meal and snack | 85% of CF patients have exocrine pancreatic insufficiency. Titrated by stool consistency and fat malabsorption symptoms. Essential for caloric absorption. |
| Vitamin Supplementation | Fat-soluble vitamins A, D, E, K daily | Malabsorbed due to pancreatic insufficiency and bile salt abnormalities. Especially important for bone health (vitamin D/K) and infection risk (vitamin A/E). |
| CF-Related Diabetes (CFRD) | Insulin (preferred over oral agents) | CFRD affects ~50% of adults. Unique — combined insulin deficiency + resistance. Insulin anabolism also helps maintain weight. Annual OGTT screening from age 10. |
| Bronchodilators | Inhaled SABA (salbutamol) before airway clearance | Used to pre-treat before physiotherapy/inhaled therapies; improves tolerance and delivery of subsequent treatments. |
| Lung Transplantation | Bilateral lung transplant | Definitive treatment for end-stage CF lung disease. Consider referral when FEV1 <30% predicted or rapid decline. Does not cure systemic CF manifestations. |
Complications
- Bronchiectasis
- Recurrent pulmonary infections
- Respiratory failure
- Hemoptysis
- Pneumothorax
- Pancreatic insufficiency
- Malnutrition
- Cystic fibrosis-related diabetes
- Liver disease
- Osteoporosis
- Infertility
- Death
Prognosis
- Cystic fibrosis is a chronic progressive disease, but survival has improved greatly with modern treatment.
- Prognosis depends mainly on:
- Severity of lung disease
- CFTR mutation
- Frequency of pulmonary exacerbations
- Nutritional status
- Presence of complications
- Early diagnosis and specialized multidisciplinary care improve outcomes.
- CFTR modulator therapy has significantly improved outcomes for many eligible patients.
Key Points / Clinical Pearls
- Cystic fibrosis is an autosomal recessive disease caused by CFTR mutations.
- Thick secretions affect multiple organs, especially the lungs and pancreas.
- Chronic cough and recurrent respiratory infections are common.
- Pancreatic insufficiency causes malabsorption and poor growth.
- The sweat chloride test is the key diagnostic test.
- Respiratory cultures guide antibiotic therapy.
- Airway clearance is a cornerstone of treatment.
- Pancreatic enzymes and nutritional support are essential in pancreatic insufficiency.
- National Center for Biotechnology Information (NIH). Cystic Fibrosis, StatPearls.
- MedlinePlus, National Library of Medicine (NIH). Cystic Fibrosis: Health Topic.
- Egan ME. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Cystic Fibrosis, an Update. Curr Opin Pediatr. 2020. PMID: 32374578.
- Lopes-Pacheco M. CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. PMC6398332.
- National Center for Biotechnology Information (NIH). Bronchiectasis, StatPearls.
Practice Cystic fibrosis (CF) questions
Lock in what you just read with exam-style MCQs and active-recall flashcards from Saturn Medic.